Questcor to Present at BIO CEO & Investor Conference 2003.

Business Editors/Health/Medical Writers

BIO CEO & Investor Conference 2003

UNION CITY, Calif.--(BUSINESS WIRE)--Feb. 21, 2003

Charles J. Casamento, Chairman, President and CEO of Questcor Pharmaceuticals, Inc. (AMEX:QSC) will give a presentation to investors on Questcor's latest reported financial results as well as its plans for continued growth and development of the Company, at the Biotechnology Industry Organization's (BIO) CEO & Investor Conference. The conference will be held at the Waldorf-Astoria Hotel in New York City on February 25-27, 2003. Mr. Casamento will make his presentation on February 27, 2003 at noon Eastern time.

The Company will also be conducting One-On-One meetings with investors and other interested parties. The Company welcomes requests for One-on-One meetings which are being facilitated via BIO's Online Meeting Request System. This system enables conference attendees to research, evaluate, request and agree to meetings requests from other attendees. Please visit the conference Web site at the following http://www.bio.org/ceo/2003/oneonone/ to access and to begin the process of requesting meetings.

The presentation will also be webcast and a replay of the presentation will be available until May 27, 2003. The webcast can be accessed through the following link: http://www.firstcallevents.com/service/ajwz375818272gf12.html

About Questcor

Questcor Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company focused on the acquisition and marketing of acute care and critical care hospital/specialty pharmaceutical and related healthcare products. Questcor currently markets five products in the U.S.: HP Acthar(R) Gel, an injectable drug that is commonly used in treating patients with infantile spasm, or West Syndrome; Ethamolin(R), an injectable drug used to treat enlarged weakened blood vessels at the entrance to the stomach that have recently bled, known as esophageal varices; Glofil(R)-125 and Inulin in Sodium Chloride, which are both injectable agents that assess how well the kidney is working by measuring glomerular filtration rate, or kidney function; and VSL#3(TM), a patented probiotic marketed as a dietary supplement, to promote normal gastrointestinal (GI) function. As part of a strategy to develop its products globally, Questcor has entered into 28 contractual relationships with public and private companies including: Ahn-Gook Pharmaceuticals of Korea; Aventis Pharmaceuticals Inc. of Bridgewater, NJ; Beacon Pharmaceuticals, Ltd. of Tunbridge Wells, Kent, United Kingdom; CSC Pharmaceuticals Handels GmbH of Vienna, Austria; Dainippon Pharmaceutical Co. Ltd., of Osaka, Japan; Orphan Australia of Melbourne, Australia; Rigel, Inc. of South San Francisco, CA; Tularik, Inc. of South San Francisco, CA and VSL Pharmaceuticals of Ft. Lauderdale, FL.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties. Such statements are subject to certain factors, which may cause Questcor's results to differ from those reported herein. Factors that may cause such differences include, but are not limited to, Questcor's ability to accurately forecast the demand for each of their products, the gross margins achieved from the sale of those products and the expenses and other cash needs for the upcoming periods, Questcor's ability to obtain finished goods from its sole source contract manufacturers on a timely basis if at all, Questcor's need for additional funding, uncertainties regarding Questcor's intellectual property and other research, development, marketing and regulatory risks, and, to the ability of Questcor to implement its strategy and acquire products and, if acquired, to market them successfully as well as the risks discussed in Questcor's report on Form 10-K for the calendar year ended December 31, 2001 and other documents filed with the Securities and Exchange Commission. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.